China Universal Asset Management Co. Ltd. Has $290,000 Stock Position in Zai Lab Limited (NASDAQ:ZLAB)

China Universal Asset Management Co. Ltd. grew its holdings in Zai Lab Limited (NASDAQ:ZLAB) by 15.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,061 shares of the company’s stock after purchasing an additional 1,502 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Zai Lab were worth $290,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC increased its stake in Zai Lab by 34.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after buying an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Zai Lab by 18.4% in the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock valued at $203,660,000 after acquiring an additional 1,312,115 shares during the last quarter. Bamco Inc. NY boosted its position in Zai Lab by 6.4% during the third quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock valued at $46,023,000 after purchasing an additional 113,869 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Zai Lab by 26.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after purchasing an additional 125,532 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Zai Lab by 28.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company’s stock worth $4,801,000 after purchasing an additional 41,128 shares during the last quarter. Institutional investors own 41.65% of the company’s stock.

Zai Lab Trading Down 2.3 %

Shares of NASDAQ ZLAB opened at $27.19 on Monday. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $36.60. The stock has a 50 day moving average of $26.67 and a 200-day moving average of $24.25. The company has a market capitalization of $2.98 billion, a P/E ratio of -9.82 and a beta of 1.00.

Insiders Place Their Bets

In other news, insider Rafael Amado sold 7,583 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares in the company, valued at $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 13.88% of the company’s stock.

Analyst Ratings Changes

ZLAB has been the subject of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on Zai Lab from $38.00 to $44.00 and gave the company an “overweight” rating in a report on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Friday, October 25th.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.